Barclays PLC Immunovant, Inc. Transaction History
Barclays PLC
- $377 Billion
- Q3 2024
A detailed history of Barclays PLC transactions in Immunovant, Inc. stock. As of the latest transaction made, Barclays PLC holds 217,812 shares of IMVT stock, worth $5.99 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
217,812
Previous 217,812
-0.0%
Holding current value
$5.99 Million
Previous $6.21 Million
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding IMVT
# of Institutions
212Shares Held
66.9MCall Options Held
2.3MPut Options Held
631K-
Vanguard Group Inc Valley Forge, PA6.66MShares$183 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.92MShares$135 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.35MShares$120 Million4.41% of portfolio
-
Armistice Capital, LLC New York, NY3.55MShares$97.6 Million1.62% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.33MShares$91.6 Million0.06% of portfolio
About Immunovant, Inc.
- Ticker IMVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 129,077,000
- Market Cap $3.55B
- Description
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...